MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Total Liabilities
Everything the company owes to creditors and other parties.
MiNK Therapeutics, Inc.NASDAQ: INKT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 11.5% from a year ago
Total liabilities stood at $23.06M at the end of Q1 FY2026, down 11.5% from a year earlier and down 19.0% from the prior quarter. Over 3 fiscal years it compounded at +9.2% a year.
Context
- Total liabilities amounted to 222.3% of total assets at the end of Q1 FY2026, down 388.4 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -11.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 28.47M USD
- Year-over-year change
- +12.5%
- 4-year CAGR
- +14.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.47M | +12.5% |
| FY2024 | 2024-12-31 | 25.31M | +11.9% |
| FY2023 | 2023-12-31 | 22.61M | +3.4% |
| FY2022 | 2022-12-31 | 21.87M | +32.8% |
| FY2021 | 2021-12-31 | 16.47M | — |
Total Liabilities vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's Mar 2026 total liabilities of $23.06M is the 3rd highest of the 9 companies compared; the peer median is $13.49M.
- Its year-over-year change of -11.5% is the 4th highest of 9, against a peer median of -20.3%.
- Total liabilities amounts to 222.3% of total assets for INKT, versus a peer median of 35.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $50.89M | -1.3% | +36.9% | 232.4% | |
| Mar 2026 | $25.72M | -21.5% | +16.2% | 216.1% | |
| Mar 2026 | $23.06M | -11.5% | +9.2% | 222.3% | |
| Mar 2026 | $21.52M | +31.8% | -15.1% | 38.3% | |
OSTXOS Therapies Incorporated | Mar 2026 | $18.12M | +398.4% | -10.5% | 248.3% |
| Mar 2026 | $8.85M | -61.7% | -2.4% | 9.0% | |
| Jun 2026 | $7.86M | -84.6% | +5.6% | 32.6% | |
| Mar 2026 | $4.73M | -19.0% | -6.6% | 25.3% | |
| Mar 2026 | $3.6M | -41.5% | -58.6% | 5.7% | |
| Peer median (excluding INKT) | $13.49M | -20.3% | -4.5% | 35.4% | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38.89M | 19.64M | 3.37M | 4.58M | 13.36M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 23K | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 721.32K | 470.3K | 177.96K | 164.24K | 211.2K |
| Total Current Assets | 39.63M | 20.4M | 3.6M | 4.99M | 13.85M |
| Property, Plant & Equipment (Net) | 606.6K | 1.07M | 953.98K | 732.93K | 390.87K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 606.6K | 1.07M | 953.98K | 732.93K | 390.87K |
| Total Assets | 40.24M | 21.47M | 4.55M | 5.72M | 14.24M |
| Account Payables | 3M | 5.82M | 3.91M | 2.73M | 3.43M |
| Short-term Debt | 0 | 0 | 0 | 0 | 5.18M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.76M | 5.21M | 5.66M | 3.51M | 2.85M |
| Total Current Liabilities | 16.47M | 12.68M | 11.4M | 6.96M | 13.03M |
| Long-term Debt | 0 | 0 | 0 | 4.92M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 9.19M | 11.21M | 13.42M | 15.44M |
| Total Non-current Liabilities | 0 | 9.19M | 11.21M | 18.35M | 15.44M |
| Total Liabilities | 16.47M | 21.87M | 22.61M | 25.31M | 28.47M |
| Common Stock | 335 | 339 | 346 | 40 | 48 |
| Retained Earnings | (82.95M) | (110.94M) | (133.4M) | (144.18M) | (156.68M) |
| Accumulated OCI | (625.27K) | (292.47K) | (430.95K) | (631.58K) | (718.92K) |
| Other Stockholders Equity | 0 | 900 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 23.78M | (401.3K) | (18.06M) | (19.59M) | (14.23M) |
| Total Debt | 0 | 0 | 0 | 4.92M | 5.18M |
| Net Debt | (38.89M) | (19.64M) | (3.37M) | 347.57K | (8.18M) |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.